Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07854847) titled 'Study Interchangeability Hep-B Vaccine Administered at Birth Dose' on Sept. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).

Primary Sponsor: PT Bio Farma

Condition: Vaccination Adverse Event Immunogenicity, Vaccine

Intervention: Biological: In-house Hepatitis B Vaccine

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 2026

Target Sample Size: 270

To know more, visit https://clinicaltrials.gov/study/NCT07854847

Published by HT Digital C...